AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
208 hedge funds and large institutions have $2.69B invested in AMAG Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 83 increasing their positions, 63 reducing their positions, and 26 closing their positions.
216% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $4.65M
50% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 26
32% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 63
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
23% more capital invested
Capital invested by funds: $2.18B → $2.69B (+$510M)
6% more funds holding
Funds holding: 197 → 208 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$87.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$32.1M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
+$28.4M |
| 5 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$17.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$59.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$55.7M |
| 3 |
PC
PointState Capital
New York
|
-$28.3M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$26.4M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$26.2M |
AMAG Hedge Fund Activity: Q2 2015 in Review
208 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2015, worth a combined $2.69B — up 23% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new AMAG positions and 26 closed out — a net gain of 13 holders — while 83 added to existing stakes and 63 trimmed.
The largest buyer was Putnam Investments, adding an estimated $87.5M. The largest seller was Adage Capital Partners, cutting an estimated $59.8M.
- 208 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2015, up from 197 in Q1 2015.
- Funds reported $2.69B of AMAG Pharmaceuticals stock for Q2 2015, up 23% quarter-over-quarter.
- 39 funds opened new AMAG Pharmaceuticals positions in Q2 2015 and 26 closed out, a net change of +13 holders.
- The largest AMAG Pharmaceuticals buyer in Q2 2015 was Putnam Investments, an estimated $87.5M added.
- The largest AMAG Pharmaceuticals seller in Q2 2015 was Adage Capital Partners, an estimated $59.8M sold.
Based on aggregated 13F filings for Q2 2015.